S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:GNPX

Genprex (GNPX) Competitors

$0.80
-0.09 (-9.75%)
(As of 04:00 PM ET)
Compare
Today's Range
$0.79
$0.92
50-Day Range
$0.76
$1.10
52-Week Range
$0.72
$2.67
Volume
717,743 shs
Average Volume
454,297 shs
Market Capitalization
$41.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

GNPX vs. AVTX, KALA, HUGE, BYSI, MDNA, MGTA, VINC, SYBX, MBIO, and NLTX

Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Avalo Therapeutics (AVTX), Kala Pharmaceuticals (KALA), FSD Pharma (HUGE), BeyondSpring (BYSI), Medicenna Therapeutics (MDNA), Magenta Therapeutics (MGTA), Vincerx Pharma (VINC), Synlogic (SYBX), Mustang Bio (MBIO), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.

Genprex vs.

Genprex (NASDAQ:GNPX) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.

9.1% of Genprex shares are owned by institutional investors. Comparatively, 67.5% of Avalo Therapeutics shares are owned by institutional investors. 10.6% of Genprex shares are owned by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genprex has higher earnings, but lower revenue than Avalo Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A-$23.74 millionN/AN/A
Avalo Therapeutics$18.05 million2.10-$41.66 million-$2.93-0.98

In the previous week, Genprex had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 7 mentions for Genprex and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.56 beat Genprex's score of 0.52 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genprex
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Avalo Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genprex has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Genprex received 192 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 64.90% of users gave Genprex an outperform vote while only 30.77% of users gave Avalo Therapeutics an outperform vote.

CompanyUnderperformOutperform
GenprexOutperform Votes
196
64.90%
Underperform Votes
106
35.10%
Avalo TherapeuticsOutperform Votes
4
30.77%
Underperform Votes
9
69.23%

Genprex has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -170.36%. Genprex's return on equity of -109.81% beat Avalo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genprex N/A -109.81% -97.89%
Avalo Therapeutics -170.36% -950.78% -85.46%

Genprex presently has a consensus price target of $3.00, suggesting a potential upside of 273.51%. Avalo Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 440.07%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Avalo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Genprex beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNPX vs. The Competition

MetricGenprexPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$41.75M$5.72B$4.47B$6.17B
Dividend YieldN/A2.71%2.41%6.19%
P/E RatioN/A5.0399.0011.90
Price / SalesN/A317.203,613.2685.61
Price / CashN/A20.4822.2322.81
Price / Book1.754.574.505.32
Net Income-$23.74M$188.65M$117.08M$193.26M
7 Day Performance2.19%-4.17%-2.86%-0.82%
1 Month Performance-1.81%1.17%0.50%1.42%
1 Year Performance-46.45%14.60%18.37%-0.91%

Genprex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTX
Avalo Therapeutics
2.1453 of 5 stars
$3.03
+1.0%
$15.50
+411.6%
-20.9%$40.00M$18.05M-1.0342Short Interest ↑
KALA
Kala Pharmaceuticals
2.1152 of 5 stars
$16.72
+1.4%
$35.50
+112.3%
+71.5%$39.29M$3.89M-1.14192
HUGE
FSD Pharma
0 of 5 stars
$1.11
+0.9%
N/A-2.3%$42.54MN/A-1.519Short Interest ↓
BYSI
BeyondSpring
1.1309 of 5 stars
$1.10
-4.3%
$1.25
+13.6%
-18.9%$42.81M$1.35M0.0091Gap Down
MDNA
Medicenna Therapeutics
1.9858 of 5 stars
$0.62
+5.1%
$2.50
+303.6%
-46.5%$43.14MN/A-4.7613Positive News
Gap Up
MGTA
Magenta Therapeutics
2.6694 of 5 stars
$0.63
-3.1%
$2.00
+215.9%
-46.2%$38.40MN/A-0.4975
VINC
Vincerx Pharma
2.3545 of 5 stars
$1.81
+12.5%
$5.50
+204.7%
+5.5%$38.36MN/A-0.6056High Trading Volume
SYBX
Synlogic
2.1726 of 5 stars
$0.56
flat
$6.83
+1,119.4%
-49.1%$38.23M$1.18M-0.6084Positive News
Gap Down
MBIO
Mustang Bio
2.2843 of 5 stars
$4.65
+8.1%
$60.00
+1,190.3%
-49.9%$37.94MN/A-0.45102Short Interest ↓
Gap Up
NLTX
Neoleukin Therapeutics
2.3778 of 5 stars
$0.88
-2.2%
$5.88
+567.6%
-18.0%$37.69MN/A-0.8691Short Interest ↓

Related Companies and Tools

This page (NASDAQ:GNPX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -